ABSTRACT

Objective: Breast cancer is the second most frequent cancer worldwide. The main therapeutic modality for breast cancer with brain metastasis is radiation. Whole Brain Radiotherapy (WBRT) is a regional treatment that provides moderate doses of radiotherapy to all brain tissue. Capecitabine was found to be effective for the treatment of breast cancer with metastasis. This study aims to determine the effectiveness of WBRT on the response of breast cancer brain metastatic lesions combined with capecitabine administration.

Methods: This study uses a prospective, randomized-blind cohort analytic study approach. Subjects were randomized into two groups by giving different fraction of WBRT and capecitabine. Subjects were evaluated 4 w post-radiation. Data on differences in patient responses in the two treatment groups were analyzed.

Results: A total of 23 breast cancer patients with brain metastasis participated in this study. Group I (WBRT 10x3Gy + capecitabine 1000 mg/m²/b.i.d) obtained results of 5 (45.5%) out of 11 are responding to therapy. Whereas in group II (WBRT 20x2Gy + capecitabine 1000 mg/m²/b.i.d) found 11 (91.7%) out of 12 patients responded to therapy. The results of statistical analysis showed that there were significant differences between the two groups with a value of P = 0.027.

Conclusion: Giving capecitabine and WBRT with 20x2Gy gives a better response both clinically and statistically.

Keywords: WBRT, Capecitabine, Breast cancer, Brain metastases
Table 1: Characteristics of subjects

| Variable                      | Group 1 (10 X 3 Gy) | Group 2 (20 X 2 Gy) | Total | P value* |
|-------------------------------|---------------------|---------------------|-------|----------|
| Age                           | 5                   | 11                  |       | 0.414    |
|                               | 8                   | 12                  |       |          |
|                               | 8                   | 12                  |       |          |
| Ethnic                        | Batak               | 3                   |       | 0.581    |
|                               | Aceh                | 3                   |       |          |
|                               | Java                | 2                   |       |          |
|                               | Chinese             | 3                   |       |          |
|                               | Malay               | 0                   |       |          |
|                               | Total               | 11                  |       |          |
|                               | 12                  | 23                  |       |          |
|                               | 10                  | 10                  |       |          |
| Education                     | Elementary          | 3                   |       | 0.423    |
|                               | Junior high school  | 1                   |       |          |
|                               | Senior high school  | 5                   |       |          |
|                               | Diploma             | 0                   |       |          |
|                               | Bachelor            | 2                   |       |          |
|                               | Total               | 11                  |       |          |
|                               | 12                  | 23                  |       |          |
|                               | 10                  | 10                  |       |          |
| Occupation                    | Housewife           | 6                   |       | 0.486    |
|                               | Private employee    | 2                   |       |          |
|                               | Entrepreneur        | 3                   |       |          |
|                               | Total               | 11                  |       |          |
|                               | 12                  | 23                  |       |          |
|                               | 10                  | 10                  |       |          |
| Overall Treatment Time        | 12-14 d             | 0                   |       | <0.001   |
|                               | 26-31 d             | 11                  |       |          |
|                               | Total               | 11                  |       |          |
|                               | 12                  | 23                  |       |          |
|                               | 10                  | 10                  |       |          |
| KPS                           | <70                 | 6                   |       | 0.089    |
|                               | ≥70                 | 5                   |       |          |
|                               | Total               | 11                  |       |          |
|                               | 12                  | 23                  |       |          |
|                               | 10                  | 10                  |       |          |
| Lesions                       | ≤3                  | 4                   |       | 0.1      |
|                               | >3                  | 7                   |       |          |
|                               | Total               | 11                  |       |          |
|                               | 12                  | 23                  |       |          |
|                               | 10                  | 10                  |       |          |
| Hb                            | <10                 | 0                   |       |          |
|                               | ≥10                 | 11                  |       |          |
|                               | Total               | 11                  |       |          |
|                               | 12                  | 23                  |       |          |
|                               | 10                  | 10                  |       |          |
| Leukocyte                     | <3,600/µl           | 0                   |       | 0.069    |
|                               | 3,600–11,000/µl     | 6                   |       |          |
|                               | >11,000/µl          | 5                   |       |          |
|                               | Total               | 11                  |       |          |
|                               | 12                  | 23                  |       |          |
|                               | 10                  | 10                  |       |          |
| Thrombocyte                   | <150,000/µl         | 0                   |       |          |
|                               | 150,000–450,000/µl  | 11                  |       |          |
|                               | >450,000/µl         | 0                   |       |          |
|                               | Total               | 11                  |       |          |
|                               | 12                  | 23                  |       |          |
|                               | 10                  | 10                  |       |          |
| AST                           | ≤45 µ/l             | 9                   |       | 0.217    |
|                               | >45 µ/l             | 3                   |       |          |
|                               | Total               | 11                  |       |          |
|                               | 12                  | 23                  |       |          |
|                               | 10                  | 10                  |       |          |
| ALT                           | ≤35 µ/l             | 5                   |       |          |
|                               | >35 µ/l             | 6                   |       |          |
|                               | Total               | 11                  |       |          |
|                               | 12                  | 23                  |       |          |
|                               | 10                  | 10                  |       |          |
| Ur                            | <13 mg/dl           | 1                   |       | 0.478    |
|                               | 13–43 mg/dl         | 10                  |       |          |
|                               | >43 mg/dl           | 0                   |       |          |
|                               | Total               | 11                  |       |          |
|                               | 12                  | 23                  |       |          |
|                               | 10                  | 10                  |       |          |
| Cr                            | <0.50 mg/dl         | 0                   |       | 0.069    |
|                               | 0.50–0.90 mg/dl     | 10                  |       |          |
|                               | >0.90 mg/dl         | 1                   |       |          |
|                               | Total               | 11                  |       |          |
|                               | 12                  | 23                  |       |          |
|                               | 10                  | 10                  |       |          |
| PA                            | Invasive Ductal Ca  | 11                  |       |          |
|                               | Invasive Lobular Ca | 0                   |       |          |
|                               | Total               | 11                  |       |          |
|                               | 12                  | 23                  |       |          |
|                               | 10                  | 10                  |       |          |
| IHK                           | ER+, PR+, HER2-     | 1                   |       | 0.392    |
|                               | ER+, PR+, HER2+     | 0                   |       |          |
|                               | ER-, PR-, HER2+     | 4                   |       |          |
|                               | ER-, PR-, HER2-     | 1                   |       |          |
|                               | No examination      | 5                   |       |          |
|                               | Total               | 11                  |       |          |
|                               | 12                  | 23                  |       |          |
|                               | 10                  | 10                  |       |          |

Based on the characteristics of the research subjects, the variables of age, ethnicity, education, occupation and menstrual status showed homogeneous results in both groups. Other variables such as KPS, lesions, hemoglobin, leukocytes, platelets, AST, ALT, Creatinine, Ureum, PA, and IHK also showed homogeneous results. Overall Treatment Time (OTT) and Cr
value data showed significant differences between the two groups, which found OTT for 12-14 d of 11 subjects (100%) in group 1 and OTT for 26-31 d of 12 subjects (100%) in group 2 (p =<0.001). And also found Cr<0.50 mg/dl of 2 subjects (100%) in group 1 and Cr>0.90 mg/dl of 6 subjects (100%) in group 2 (p = 0.01).

Table 2: The correlation between subject characteristic and therapeutics response

|                      | Responder | Non-Responder | Total | P value* |
|----------------------|-----------|---------------|-------|----------|
|                      | n        | %            | n     | %        |
| **Age**              |          |              |       |          |
| <50                  | 9        | 69.2         | 4     | 30.8     | 13     |
| <50                  | 16       | 69.6         | 7     | 30.4     |
| **Ethnic**           |          |              |       |          |
| Batak                | 7        | 87.5         | 1     | 12.5     | 8      |
| Aceh                 | 3        | 60           | 2     | 40       | 5      |
| Java                 | 3        | 60           | 2     | 40       | 5      |
| Chinese              | 2        | 50           | 2     | 50       | 4      |
| Malay                | 1        | 100          | 0     | 0        | 1      |
| **Education**        |          |              |       |          |
| Elementary           | 3        | 75           | 5     | 25       | 4      |
| Junior high school   | 3        | 60           | 2     | 40       | 5      |
| Senior high school   | 6        | 66.7         | 3     | 33.3     | 9      |
| Diploma              | 1        | 100          | 0     | 0        | 1      |
| Bachelor             | 3        | 75           | 1     | 25       | 4      |
| **Occupation**       |          |              |       |          |
| Housewife            | 10       | 71.4         | 4     | 28.6     | 14     |
| Private employee     | 4        | 80           | 1     | 20       | 5      |
| Entrepreneur         | 2        | 50           | 2     | 50       | 4      |
| **Menstrual Status** |          |              |       |          |
| Pre-Menopause        | 13       | 92.9         | 1     | 7.1      | 14     |
| Menopause            | 3        | 33.3         | 6     | 66.7     | 9      |
| **Overall Treatment Time** |    |              |       |          |
| 12-14 d              | 11       | 91.7         | 1     | 8.3      | 12     |
| 26-31 d              | 5        | 45.5         | 6     | 54.5     | 11     |
| **KPS**              |          |              |       |          |
| <70                  | 6        | 75           | 2     | 25       | 8      |
| ≥70                  | 10       | 66.7         | 5     | 33.3     | 15     |
| **Lesions**          |          |              |       |          |
| ≤3                   | 12       | 92.3         | 1     | 7.7      | 13     |
| >3                   | 4        | 40           | 6     | 60       | 10     |
| **Hb**               |          |              |       |          |
| <10                  | 0        | 0            | 0     | 0        | 0      |
| ≥10                  | 16       | 69.6         | 7     | 30.4     | 23     |
| **Leukocyte**        |          |              |       |          |
| <3.600/µl            | 0        | 0            | 0     | 0        | 0      |
| 3.600–11,000/µl      | 13       | 76.5         | 4     | 23.5     | 17     |
| >11,000/µl           | 3        | 50           | 3     | 50       | 6      |
| **Thrombocyte**      |          |              |       |          |
| <150,000/µl          | 0        | 0            | 0     | 0        | 0      |
| 150,000–450,000/µl   | 16       | 69.9         | 6     | 30.4     | 23     |
| >450,000/µl          | 0        | 0            | 0     | 0        | 0      |
| **AST**              |          |              |       |          |
| ≤ 45 µ/l             | 15       | 71.4         | 6     | 28.6     | 21     |
| >45 µ/l              | 1        | 50           | 1     | 50       | 2      |
| **ALT**              |          |              |       |          |
| ≤ 35 µ/l             | 7        | 63.6         | 4     | 36.4     | 11     |
| >35 µ/l              | 9        | 75           | 3     | 25       | 12     |
| **Ur**               |          |              |       |          |
| <13 mg/dl            | 0        | 0            | 0     | 0        | 0      |
| 13–43 mg/dl          | 16       | 72.7         | 6     | 27.3     | 22     |
| >43 mg/dl            | 0        | 0            | 0     | 0        | 0      |
| **Cr**               |          |              |       |          |
| <0.5 mg/dl           | 0        | 0            | 0     | 0        | 0      |
| 0.50–0.90 mg/dl      | 10       | 62.5         | 6     | 37.5     | 16     |
| >0.90 mg/dl          | 6        | 85.7         | 1     | 14.3     | 7      |
| **PA**               |          |              |       |          |
| Invasive Ductal Ca   | 16       | 69.6         | 7     | 30.4     | 23     |
| Invasive Lobular Ca  | 0        | 0            | 0     | 0        | 0      |
| **IHK**              |          |              |       |          |
| ER+, PR+, HER2+      | 2        | 100          | 0     | 0        | 2      |
| ER+, PR+, HER2+      | 2        | 66.7         | 1     | 33.3     | 3      |
| ER-, PR+, HER2+      | 6        | 85.7         | 1     | 14.3     | 7      |
| ER-, PR+, HER2-      | 0        | 0            | 1     | 100      | 1      |
| No examination       | 6        | 60           | 4     | 40       | 10     |
| **Total**            | 16       | 69.6         | 7     | 30.4     | 23     |
The characteristics of the research subjects, the variables of age, ethnicity, education, occupation, KPS and lesions showed no significant correlation to therapeutic response. Other variables such as hemoglobin, leukocytes, platelets, AST, ALT, Creatinine, Ureum, PA, and BHK also showed no significant correlation to therapeutic response. The characteristics that shown significant correlation were Menstrual Status, OTT and Lesions.

| Table 3: The result of response |
|-----------------|-----------------|-----------------|-----------------|-----------------|
|                | Responder | Non-Responder | Total | P value* |
|----------------|-----------|---------------|-------|----------|
| Group 1        | 5         | 6             | 11    | 0.027    |
| Group 2        | 11        | 1             | 12    |          |
| Total          | 16        | 6             | 23    |          |

The results of responses to WBRT and capecitabine showed significant differences between groups. Group I (WBRT 10x3Gy + capcitabine 1000 mg/m²/b.i.d) obtained results of 5 (45.5%) responding to therapy. Whereas in group II (WBRT 20x2Gy + capcitabine 1000 mg/m²/b.i.d) found 11 (91.7%) patients responded to therapy. The results of statistical analysis showed that there were significant differences between the two groups with a value of P = 0.027.

DISCUSSION

Subject characteristics

Brain metastatic breast cancer can occur in women of all ages. In this study, the highest number of subjects was found in the age range <50 y. This is consistent with research conducted by Chargari, in 2009 where the average age of the most frequently found was 38-53 y.

Response to WBRT + capcitabine

In this study, there were more respondents in group 2, WBRT 20x2Gy + capcitabine with 12 subjects (91.7%). Clinically, there are more respondents in group 2. By giving WBRT 20x, then the dose of capcitabine will also increase. As capcitabine is increased, the radio sensitizer effect will also increase during WBRT. In a study conducted by Cyrus, in 2009 by giving 10X5Gy+capcitabine, 1000 mg/m² obtained 60% responder results. WBRT 20x2Gy is well tolerated and considered in patients with SPK ≥ 70 with solitary or multiple lesions; this was stated in a study conducted by Noordijk et al., in 1994.

In this study, statistically, the results were obtained p = 0.027, in which there was a response relationship between the groups and WBRT + capcitabine.

Factors that affect the study

There are many factors that affect this study, one of which is the time of the study. The duration of the study was also influenced by several factors, such as rare cases such as breast cancer with brain metastases. Also, the issue of subject availability agreed to therapy, such as socioeconomic problems in patients. Because most patients come from out of town and are required to stay near the hospital during therapy. Patients must find a place to stay and eat alone. Another factor is family support, because it is far from the place of origin, so support from the family is also very little.

The availability of resources in Indonesia is also very limited, where the LINAC devices that can use SRS or SRT technique are also limited. Because of this limitation, this study uses WBRT.

The dose of the capcitabine used is 1000mg/m²/b.i.d because the drug preparations in Indonesia are only 500 mg per tablet. Abroad, there are 2 preparations of Capcitabine, namely 500 mg/tab and 150 mg/tab.

ACKNOWLEDGMENT

Further research is expected to be carried out to assess survival rates and the relationship of therapeutic response to survival rates. In addition, it is recommended to provide 500 mg/tab and 150 mg/tab capcitabine preparation and LINAC devices that can do the SRS technique in Indonesia.

FUNDING

Nil

AUTHORS CONTRIBUTIONS

All the authors have contributed equally.

CONCLUSION

In this study, the administration of capcitabine and 20 x 2gy fractions gave a better response both clinically and statistically (p = 0.027).

REFERENCES

1. American Cancer Society. Cancer Treatment and Survivorship Facts and Figures; 2014.
2. Lu J, Steeg PS, Price JE. Breast cancer metastasis: challenges and opportunities. Cancer Res 2009;69:4951-3.
3. Devita H, Rosenberg's. Brain Metastasis. Cancer principles and practice of oncology. 9th edition. Lippincott Williams and Wilkins; 2011.
4. Patchell RA, Regine WF. Brain Metastase: Whole Brain Radiation Therapy Perspective. Principles and Practice of Stereotactic Radiotherapy; 2008; p. 201-5.
5. Rivera E, Meyers C, Groves M. Phase I study of capcitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. Cancer 2006;107:1548–54.
6. McEvoy GK. editor. Capcitabine. In: AHFS drug information. Bethesda MD: American Society of Health-System Pharmacists; 2002. p. 916–21.